递送有效载荷的工程化γδ T细胞在骨肉瘤临床前模型中显示增强的细胞毒性、持久性和疗效
研究构建了分泌GD2特异性调理素(scFv-Fc融合蛋白)和IL-15Rα-IL-15融合蛋白(stIL15)的Vγ9Vδ2 T细胞(stIL15-OPS-γδ T细胞),在临床前骨肉瘤模型中显示增强的细胞毒性、旁观者免疫激活、体内肿瘤控制及血液持久性,且对患者来源骨肉瘤有效,联用唑来膦酸可增强疗效。
要点
- stIL15-OPS-γδ T细胞分泌GD2特异性调理素和stIL15,具有增强的细胞毒性并促进旁观者免疫细胞活性。
- stIL15分泌免除对外源性细胞因子补充的需求,并介导旁观者自然杀伤细胞的激活。
- 与未修饰γδ T细胞相比,stIL15-OPS-γδ T细胞在体内对皮下肿瘤的控制和血液持久性更优。
核心结论
- stIL15-OPS-γδ T细胞被确定为候选同种异体细胞治疗平台,结合直接细胞溶解与旁观者激活以促进肿瘤控制。
研究设计与样本
- 工程化γδ T细胞平台技术研究,基于Vγ9Vδ2 T细胞的先天特性,构建分泌scFv-Fc融合蛋白和stIL15的细胞。
- 使用GD2作为模型抗原,在临床前骨肉瘤模型(包括患者来源骨肉瘤的动物模型和体外实验)中评估。
主要发现
- stIL15-OPS-γδ T细胞具有增强的细胞毒性,并促进其他淋巴和髓系细胞的旁观者活性。
- stIL15分泌免除对外源性细胞因子补充的需求,并进一步介导旁观者自然杀伤细胞的激活。
- 与未修饰γδ T细胞相比,stIL15-OPS-γδ T细胞在体内对皮下肿瘤的控制和血液持久性更优。
- stIL15-OPS-γδ T细胞在动物模型和体外对患者来源骨肉瘤有效,加入唑来膦酸可增强疗效。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T cell-based cancer immunotherapy has typically relied on membrane-bound cytotoxicity enhancers such as chimeric antigen receptors expressed in autologous αβ T cells. These approaches are limited by tonic signaling of synthetic constructs and costs associated with manufacturing. γδ T cells are an emerging alternative for cellular therapy, having innate antitumor activity, potent antibody-dependent cellular cytotoxicity, and minimal alloreactivity. We present an immunotherapeutic platform technology built around the innate properties of the Vγ9Vδ2 T cell, harnessing specific characteristics of this cell type and offering an allocompatible cellular therapy that recruits bystander immunity. We engineered γδ T cells to secrete synthetic tumor-targeting opsonins in the form of an scFv-Fc fusion protein and a mitogenic IL-15Rα-IL-15 fusion protein (stIL15). Using GD2 as a model antigen, we show that GD2-specific opsonin-secreting Vγ9Vδ2 T cells (stIL15-OPS-γδ T cells) have enhanced cytotoxicity and promote bystander activity of other lymphoid and myeloid cells. Secretion of stIL-15 abrogated the need for exogenous cytokine supplementation and further mediated activation of bystander natural killer cells. Compared with unmodified γδ T cells, stIL15-OPS-γδ T cells exhibited superior in vivo control of subcutaneous tumors and persistence in the blood. Moreover, stIL15-OPS-γδ T cells were efficacious against patient-derived osteosarcomas in animal models and in vitro, where efficacy could be boosted with the addition of zoledronic acid. Together, the data identify stIL15-OPS-γδ T cells as a candidate allogeneic cell therapy platform combining direct cytolysis with bystander activation to promote tumor control.
引用
- Fowler D, Barisa M, Southern A, et al. Payload-delivering engineered γδ T cells display enhanced cytotoxicity, persistence, and efficacy in preclinical models of osteosarcoma. Sci Transl Med. 2024. PMID: 38809963. doi:10.1126/scitranslmed.adg9814
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。